Related Experiment Videos
Iron requirements in hemodialysis
John A Sargent1, Sergio R Acchiardo
1Quantitative Medical Systems, Inc, Emeryville, Calif 94608, USA. john@qms-us.com
Blood Purification
|January 21, 2004
Summary
Intravenous iron preloading improved hematocrits in dialysis patients. Significant blood loss was identified, potentially exacerbated by frequent dialysis, impacting anemia management.
Area of Science:
- Nephrology
- Hematology
Background:
- Anemia correction in dialysis patients using erythropoietin (EPO) is often hindered by iron deficiency.
- Intravenous iron administration is a strategy to overcome this limitation.
Purpose of the Study:
- To evaluate the efficacy of intravenous iron preloading in dialysis patients.
- To quantify blood loss in dialysis patients, particularly in the context of frequent or daily dialysis.
Main Methods:
- Patients received 900-1,525 mg of intravenous iron as preloading.
- Blood loss was assessed through various routes including sampling, dialyzer clotting, and postdialysis bleeding.
- Annual blood loss was projected based on these measurements.
Main Results:
- 70% of patients showed increased hematocrits (HCTs) without EPO administration.
- 40% of patients achieved HCTs greater than 30% post-iron preloading.
- Projected annual blood loss ranged from 2,516 to 5,126 ml, comparable to early dialysis eras.
Conclusions:
- Intravenous iron preloading can effectively improve hematocrit levels in dialysis patients.
- Significant blood loss occurs during dialysis, posing a challenge for anemia management.
- Daily dialysis may substantially increase annual red cell loss, necessitating careful iron monitoring.